Atherid Therapeutics
A first-in-class molecule designed to clear plaque cholesterol and lipids from artery walls for the treatment of atherosclerosis.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | $750k | Grant | |
| Total Funding | 000k | ||
Related Content
Atherid Therapeutics is a preclinical-stage biopharmaceutical entity focused on developing a treatment for atherosclerosis, the buildup of cholesterol and fats in artery walls that can lead to severe cardiovascular events. The company's lead candidate is ATH01, a first-in-class molecule engineered to directly target and clear these arterial plaques.
The drug's mechanism is based on a naturally occurring protein combined with a smaller molecule that guides it to the plaque deposits. This approach aims to address the root cause of atherosclerosis, a condition that affects a broad population, particularly those with risk factors like high cholesterol, diabetes, or peripheral arterial disease (PAD).
After a decade of research, including testing on human tissue and in animal models, the company is preparing for final preclinical studies. The objective is to initiate human clinical trials within the next two years, positioning ATH01 as a potential therapeutic for a significant unmet medical need in cardiovascular health.
Keywords: Atherosclerosis, cardiovascular disease, drug development, plaque cholesterol, ATH01, preclinical, biopharmaceutical, targeted drug delivery, peripheral arterial disease, lipid reduction